



EPICS

# Lymphoma in 2022 and Beyond

September 8 and 9, 2022

Content	Slide
Meeting Snapshot	3 ➔
Faculty Panel	4 ➔
Meeting Agenda	5 ➔
Strategic Recommendations	7 ➔
Summaries of Faculty Presentations	9 ➔
Key Insights	20 ➔

EPICS

## VIRTUAL CLOSED-DOOR ROUNDTABLE




**DATE:**  
September 8 and 9,  
2022



**PANEL:** Key experts in  
lymphoma and CLL  
> 6 from US  
> 2 from Europe



**DISEASE STATE AND  
DATA PRESENTATIONS**  
by key experts



**INSIGHTS REPORT**  
including postmeeting  
analyses and actionable  
recommendations



**LYMPHOMA/CLL-SPECIFIC  
DISCUSSIONS** on  
therapeutic advances and  
their application in clinical  
decision-making

# Panel Consisting of 6 US and 2 European Lymphoma Experts

EPICS



**Matthew Lunning, DO, FACP**  
University of Nebraska  
Medical Center



**CHAIR:**  
**Brad Kahl, MD**  
Washington University  
School of Medicine

**John N. Allan, MD**  
Weill Cornell Medicine

**Peter Martin, MD**  
Weill Cornell Medicine



**Stefan Barta, MD, MS,  
MRCP UK**  
Penn Medicine

**Matthew Matasar, MD**  
Memorial Sloan Kettering  
Cancer Center

**Georg Hess, MD**  
Johannes Gutenberg University

**Pier Luigi Zinzani, MD, PhD**  
University of Bologna Institute of  
Hematology and Medical Oncology

# Meeting Agenda Day 1

EPICS

Time (EDT)	Topic	Speaker/Moderator
10.00 AM – 10.05 AM	Welcome, Introductions, and Meeting Objectives	Brad Kahl, MD
10.05 AM – 10.25 AM	Advances in CLL/SLL	John N. Allan, MD
10.25 AM – 10.40 AM	Role of Fixed-Duration and MRD-Guided Strategies in CLL	John N. Allan, MD
10.40 AM – 11.20 AM	Discussion	Brad Kahl, MD
11.20 AM – 11.30 AM	Key Messages	John N. Allan, MD
11.30 AM – 11.40 AM	Break	
11.40 AM – 12.00 PM	Advances in Follicular Lymphoma	Pier Luigi Zinzani, MD, PhD
12.00 PM – 12.20 PM	Discussion	Brad Kahl, MD
12.20 PM – 12.25 PM	Key Messages	Pier Luigi Zinzani, MD, PhD
12.25 PM – 12.35 PM	Advances in T-Cell Lymphoma	Stefan K. Barta, MD, MS, MRCPCUK
12.35 PM – 12.50 PM	Discussion	Brad Kahl, MD
12.50 PM – 12.55 PM	Key Messages	Stefan K. Barta, MD, MS, MRCPCUK
12.55 PM – 1.00 PM	Wrap-up and Overview of Day 2 Activities	Brad Kahl, MD

# Meeting Agenda Day 2

EPICS

Time (EDT)	Topic	Speaker/Moderator
10.00 AM – 10.05 AM	Welcome and Review Agenda for Day 2	Brad Kahl, MD
10.05 AM – 10.20 AM	Advances in Marginal Zone Lymphoma	Matthew J. Matasar, MD
10.20 AM – 10.45 AM	Discussion	Brad Kahl, MD
10.45 AM – 10.50 AM	Key Messages	Matthew J. Matasar, MD
10.50 AM – 11.10 AM	Advances in DLBCL/Aggressive B-Cell Lymphoma	Matthew Lunning, DO, FACP
11.10 AM – 11.30 AM	Discussion	Brad Kahl, MD
11.30 AM – 11.35 AM	Key Messages	Matthew Lunning, DO, FACP
11.35 AM – 11.45 AM	Break	
11.45 AM – 12.00 PM	Advances in Mantle Cell Lymphoma	Georg Hess, MD
12.00 PM – 12.20 PM	Discussion	Brad Kahl, MD
12.20 PM – 12.25 PM	Key Messages	Georg Hess, MD
12.25 PM – 12.40 PM	Advances in Waldenström Macroglobulinemia	Peter Martin, MD
12.40 PM – 1.00 PM	Discussion	Brad Kahl, MD
1.00 PM – 1.05 PM	Key Messages	Peter Martin, MD
1.05 PM – 1.10 PM	Wrap-up and Close	Brad Kahl, MD



EPICS

# Summaries of Faculty Presentations




# Advances in CLL/SLL (1/2)

Presented by John N. Allan, MD

EPICS

- > With the establishment of BTK inhibitors as





# Advances in CLL/SLL (2/2)

Presented by John N. Allan, MD

EPICS

- The poor outcomes with del(11q) have also been overcome with BTK inhibitors, as seen in subset analyses in RESONATE-2 and



# Role of Fixed-Duration and MRD-Guided Strategies in CLL

EPICS

Presented by John N. Allan, MD

- > Several trials have been carried out to evaluate combinations





# Advances in Follicular Lymphoma (1/2)

Presented by Pier Luigi Zinzani, MD, PhD

EPICS

- > Updated guidelines for follicular lymphoma

*Management of follicular lymphoma – HIGH TUMOR BURDEN*



# Advances in Follicular Lymphoma (2/2)

Presented by Pier Luigi Zinzani, MD, PhD

EPICS

- > Approved regimens for patients with previously treated FL include rituximab-lenalidomide, CAR T cells (US, EU), mosunetuzumab (EU), and



# Advances in T-Cell Lymphoma

Presented by Stefan K. Barta, MD, MS, MRCP UK

EPICS

- > The phase III ECHELON-2 trial compared brentuximab vedotin + CHP

ECHELON-2: 5-year Follow-up for sALCL



# Advances in Marginal Zone Lymphoma

Presented by Matthew J. Matasar, MD

EPICS

- > Marginal zone lymphoma (MZL) is a diverse disease with 3





# Advances in DLBCL/Aggressive B-Cell Lymphoma

Presented by Matthew Lunning, DO, FACP

EPICS

- > For patients with diffuse large B-cell lymphoma





# Advances in Mantle Cell Lymphoma

Presented by Georg Hess, MD

EPICS

- > Patients with newly diagnosed mantle cell lymphoma (MCL)





# Advances in Waldenström Macroglobulinemia

Presented by Peter Martin, MD

EPICS

- > Recommendations for patients with newly



EPICS

# Key Insights

# Advances in CLL/SLL (1/2)

EPICS

## First-Line Therapy and Risk Factors

Regarding first-line BTK inhibitor of choice in CLL, most of the experts favor acalabrutinib (n = 4; for 2 of these, zanubrutinib is not available



# Advances in CLL/SLL (2/2)

EPICS

## First-Line Therapy (cont) and R/R CLL

- > Scenario 2: A patient with newly diagnosed CLL and unmutated

## COVID-19

The experts discussed how the COVID-19 pandemic affected use of



# Role of Fixed-Duration and MRD-Guided Strategies in CLL

EPICS

The experts discussed the potential approval of time-limited ibrutinib-venetoclax on the basis of the GLOW and CAPTIVATE trials



# Advances in Follicular Lymphoma (1/2)

EPICS

## Treatment Sequencing in FL

The experts discussed how they choose among different therapeutic options in FL in the context of clinical scenarios



# Advances in Follicular Lymphoma (2/2)

EPICS

BTK inhibitors were historically not viewed as active in patients with FL, but expert opinion is that the ROSEWOOD trial may provide the rationale



# Advances in T-Cell Lymphoma (1/2)

EPICS

## First-Line Therapy in TCL

For a patient with newly diagnosed, CD30-positive TCL, expert recommendation is BV-CHP in younger patients, since brentuximab vedotin is



# Advances in T-Cell Lymphoma (2/2)

EPICS

The experts generally offer ASCT consolidation to patients with TCL who achieve a response to first-line therapy and for whom transplant is not contraindicated.



# Advances in Marginal Zone Lymphoma

EPICS

## First-Line Therapy in MZL Subtypes

The experts discussed initial therapy for patients with MZL



# Advances in DLBCL/Aggressive B-Cell Lymphoma

EPICS

Expert opinion is that the ABC/GCB classification of DLBCL does not have a solid biologic basis and will likely be replaced by a molecular-based



# Advances in Mantle Cell Lymphoma (1/2)

EPICS

## Assessment of the SHINE Trial

The experts demonstrated varying degrees of enthusiasm for the SHINE regimen of ibrutinib-BR followed by rituximab maintenance and



# Advances in Mantle Cell Lymphoma (2/2)

EPICS

## High-Dose Cytarabine Before Transplant

Currently, the experts do incorporate high-dose cytarabine in younger patients with MCL who are being considered for stem cell transplantation



# Advances in Waldenström Macroglobulinemia

EPICS

## First-Line Therapy in WM

For patients with newly diagnosed WM, the experts generally use bendamustine and rituximab

